Inhibikase Therapeutics, Inc. 8-K

What Happened
Inhibikase Therapeutics, Inc. announced its financial results for the year ended December 31, 2025 and other corporate updates in a press release dated March 26, 2026. The company furnished that press release as Exhibit 99.1 to a Current Report on Form 8-K (Item 2.02). The 8-K states the furnished information is not “filed” for purposes of Section 18 of the Securities Exchange Act and is not incorporated by reference into other filings except where expressly stated.

Key Details

• Date of announcement: March 26, 2026 (Form 8-K filed the same day).
• Reporting period: Full year ended December 31, 2025 (financial results reported).
• Exhibit furnished: Press release attached as Exhibit 99.1 to the 8-K.
• Technical exhibit: Inline XBRL Cover Page Interactive Data File included as Exhibit 104.
• Disclosure status: Information is furnished (Item 2.02) and expressly not deemed “filed” under Section 18.

Why It Matters
This filing notifies investors that Inhibikase has released its full-year 2025 earnings and related corporate updates; investors should review the attached press release (Exhibit 99.1) for details on revenue, net loss/profit, cash position, guidance or other material metrics. Because the company furnished the press release rather than “filed” it, liability protections differ under the Exchange Act—investors should monitor follow-up filings (e.g., 10-K or subsequent 8-Ks) for audited financial statements and any items formally incorporated by reference.